Bosutinib

Last Updated: 09/19/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 861 publications

Chronic-phase chronic myeloid leukemia complicated by dasatinib-associated lymphadenopathy

Chronic-phase chronic myeloid leukemia complicated by dasatinib-associated lymphadenopathy

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 30, 2026

Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomes.

Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomes.

Journal: Expert review of hematology

Published: August 12, 2026

Allosteric kinase inhibition in hematological malignancies: from asciminib to emerging regulatory sites.

Allosteric kinase inhibition in hematological malignancies: from asciminib to emerging regulatory sites.

Journal: Biochemical pharmacology

Published: July 10, 2026

Simultaneous determination of bosutinib and its metabolite in rat plasma by UPLC-MS/MS: Development, validation and application to pharmacokinetic and metabolic stability studies.

Simultaneous determination of bosutinib and its metabolite in rat plasma by UPLC-MS/MS: Development, validation and application to pharmacokinetic and metabolic stability studies.

Journal: Chemico-biological interactions

Published: June 28, 2026

Synthesis and in silico evaluation of novel hybrid 1,4-benzothiazine-1,1-dioxide-bis(1,2,3-triazole) derivatives as potential SRC kinase inhibitors via 1,3-dipolar cycloaddition.

Synthesis and in silico evaluation of novel hybrid 1,4-benzothiazine-1,1-dioxide-bis(1,2,3-triazole) derivatives as potential SRC kinase inhibitors via 1,3-dipolar cycloaddition.

Journal: Computational biology and chemistry

Published: June 15, 2026

Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives.

Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives.

Journal: ClinicoEconomics and outcomes research : CEOR

Published: May 30, 2026

Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data.

Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data.

Journal: Blood reviews

Published: May 19, 2026

Treatment Discontinuation of First-Line Bosutinib in a Real-World Cohort of Patients With Chronic Myeloid Leukemia: Impact of Hepatic Toxicity.

Treatment Discontinuation of First-Line Bosutinib in a Real-World Cohort of Patients With Chronic Myeloid Leukemia: Impact of Hepatic Toxicity.

Journal: Cureus

Published: May 06, 2026

A novel hyperactive BCR::ABL1 e6a3 variant confers resistance to combined asciminib plus ponatinib therapy.

A novel hyperactive BCR::ABL1 e6a3 variant confers resistance to combined asciminib plus ponatinib therapy.

Journal: medRxiv : the preprint server for health sciences

Published: May 04, 2026

Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib leads to Potent and Selective Quinoline-based HIPK4 Inhibitor AZ137.

Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib leads to Potent and Selective Quinoline-based HIPK4 Inhibitor AZ137.

Journal: bioRxiv : the preprint server for biology

Published: May 04, 2026

A CML Patient with Unintentional Bosutinib Exposure During the First Trimester of Pregnancy

A CML Patient with Unintentional Bosutinib Exposure During the First Trimester of Pregnancy

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: April 27, 2026

Src Family Kinase Inhibitors Bosutinib and Dasatinib Enhance ATRA-induced Differentiation of NB4 Leukemia Cells.

Src Family Kinase Inhibitors Bosutinib and Dasatinib Enhance ATRA-induced Differentiation of NB4 Leukemia Cells.

Journal: Anticancer research

Published: April 16, 2026

Showing 1-12 of 861

Last Updated: 09/19/2026